ESTEVE's 2024 Revenue Grows by 5% as It Pursues Specialized Medicine Goals

ESTEVE Reports Increase in Net Revenue and Strategic Focus for Specialized Medicine

In a significant milestone, ESTEVE, a prominent pharmaceutical company based in Barcelona, has reported its annual results for 2024, revealing a net revenue of €744 million. This figure marks a 5% increase compared to the previous year, demonstrating the company's robust growth trajectory and commitment to enhancing patient care through specialized treatments.

Financial Overview

The results highlight the company's strategic focus on international expansion, with overseas sales constituting 75% of its total revenue. Specifically, Spain accounts for 25% of revenue, while the fastest-growing sectors are other European Union countries at 53%, followed by other international markets contributing 22%.

This financial performance is underpinned by strong contributions from its Pharma Business, which experienced over 15% growth in net revenues. Additionally, although the Contract Development and Manufacturing Organization (CDMO) division maintained stable revenues, it positively impacted the overall financial results through a more value-added product mix.

Strategic Acquisitions

A pivotal factor in ESTEVE's revenue enhancement has been its acquisition of HRA Pharma Rare Diseases in July 2024. This strategic move introduces three new treatment options focused on rare diseases, including Cushing's syndrome. By integrating these new therapies, ESTEVE is not only expanding its portfolio but also reinforcing its commitment to addressing unmet medical needs in both European and American markets.

Looking ahead to 2025, ESTEVE will continue its shift towards specialized therapies, highlighted by plans to acquire an essential treatment for high-grade resectable non-metastatic osteosarcoma. Furthermore, the company has recently secured licensing for a biological product aimed at treating severe insulin-like growth factor 1 deficiency in children and adolescents aged 2 to 18.

Commitment to Innovation

Investing in innovation remains a cornerstone of ESTEVE's strategy, with a commitment of €46 million directed towards development initiatives, constituting more than 6% of net revenues. This investment aims to enhance both product and process development. The company is also expanding its industrial capacity with new production facilities, including one relocating its current operations in China, and another dedicated to manufacturing pharmaceutical active ingredients in Celrà, Spain.

Social Responsibility and Impact

ESTEVE's growth isn't solely rooted in financial metrics; the company has positively impacted the lives of 8 million patients in 2024. Its efforts to improve the quality of life for those suffering from conditions in endocrinology, oncology, and pain management underscore its mission to produce effective therapies.

In alignment with its values, ESTEVE has invested over €1.3 million in sustainability and diversity initiatives. The company witnessed a 6.6% increase in its workforce and achieved gender balance in management, with women occupying 50% of leadership roles.

Commitment to Sustainability

In 2024, ESTEVE has furthered its sustainability efforts as part of its ambition to achieve carbon neutrality by 2050. The company achieved a 5.8% reduction in its carbon footprint since 2023 and a notable 12% decrease in water consumption compared to the prior year, reinforcing its commitment to environmental responsibility. ESTEVE has also successfully transitioned to using 100% renewable electricity in its operations.

Conclusion

As ESTEVE looks to the future, the results of 2024 signal not just a consolidation of growth but also a heartfelt commitment to improving people's lives through specialized healthcare solutions. With a strategic focus on innovation and expansion, ESTEVE is poised to navigate the challenges and opportunities ahead in the evolving pharmaceutical landscape. "We believe 2025 will be pivotal for our journey as a leading international pharmaceutical company focused on specialized medicine," stated Staffan Schüberg, CEO of ESTEVE.

For more details, readers can visit ESTEVE's official website or contact their communication team for inquiries.